FDA Targets 6-Month-Olds, Approves New Bivalent COVID Vaccine For Infants

  • “More children now have the opportunity to update their protection against COVID-19 with a bivalent COVID-19 vaccine, and we encourage parents and caregivers of those eligible to consider doing so,” FDA Commissioner Robert M. Califf stated in a press release.
  • The announcement from the FDA flies in the face of a new study showing that a rising COVID subvariant called BQ.1.1,  is emerging as the dominant form in the United States and is proving much more resistant to the new bivalent vaccines than other variants present in the country.
  • “The BA-5-bivalent booster did not produce robust neutralization against the newly emerged BA.2.75.2, BQ.1.1,  or XBB.1,” the study asserted.
Click to read full article Go back home

Sign Up for Our Newsletter

Join our list!

Sign up here to get our daily newsletter with the top trending headlines.